These press releases are for business and financial media.
-
- 20 December 2000
- SENIOR APPOINTMENTS AT ASTRAZENECA AstraZeneca today announced the appointment of Bruno Angelici as Executive Vice President, International Sales and Marketing in succession to Mike O'Brien who is retiring.
-
- 19 December 2000
- ASTRAZENECA WINS LOSEC® PATENT LITIGATION IN CANADA The Federal Court of Canada has ruled in favour of AstraZeneca in litigation between AstraZeneca and RhoxalPharma Inc. under the Patented Medicines (Notice Of Compliance) Regulations.
-
- 14 December 2000
- ASTRAZENECA GAINS JAPANESE APPROVAL FOR TWO MAJOR TREATMENTS - TWO MORE EXPECTED BEFORE YEAR END AstraZeneca today announced it has received approval from the Japanese Ministry of Health and Welfare (MWH) for Seroquel®, one of its major pharmaceuticals, and two significant line extensions for omeprazole, the company's largest product worldwide. In addition, AstraZeneca expects two further major new pharmaceuticals to be approved in Japan before the end of 2000.
-
- 12 December 2000
- ASTRAZENECA REPORTS CONTINUED STRONG PROGRESS ACROSS R&D PORTFOLIO AstraZeneca today presents an R&D update to a meeting of analysts, at its Mölndal site in Sweden.
-
- 07 December 2000
- ASTRAZENECA RELEASES ENCOURAGING PHASE III DATA ON ICI182780 (FASLODEX®) - A NEW TYPE OF ADVANCED BREAST CANCER DRUG OFFERING A POTENTIAL NEW OPTION TO ONCOLOGY COMMUNITY Data presented today at the 23rd annual San Antonio Breast Cancer Symposium suggest that AstraZeneca's ICI182780 (Faslodex®) is at least as effective as Arimidex® , the most widely prescribed aromatase inhibitor, in treating advanced breast cancer in post-menopausal women who have failed initial hormonal treatment.
-
- 21 November 2000
- ASTRAZENECA FILES ZOMIG® NASAL SPRAY IN EUROPE AstraZeneca announced today that it has submitted its first regulatory application in Europe for Zomig (zolmitriptan) Nasal Spray for the acute treatment of migraine with or without aura. This new treatment will be reviewed under the Mutual Recognition procedure with Sweden acting as the reference member state. This is the first filing of a second-generation triptan for a nasal spray formulation.
-
- 17 November 2000
- SWEDISH COURT RULES IN ASTRAZENECA's FAVOUR IN OMEPRAZOLE SPC CASE AstraZeneca today announced that the Stockholm District Court has ruled that Scand Pharm's generic omeprazole product infringes AstraZeneca's Supplementary Patent Certificate (SPC) for omeprazole, which provides protection until November 15, 2002.
-
- 15 November 2000
- ASTRAZENECA REMAINS COMMITTED TO STROKE TREATMENT RESEARCH FOLLOWING STUDY FINDINGS FOR ZENDRA AstraZeneca today announced that development of Zendra (clomethiazole) has been stopped following analysis of findings from the Class-I study which showed no efficacy benefits for patients suffering acute cases of stroke.
-
- 13 November 2000
- DEALINGS COMMENCE IN SYNGENTA AG AstraZeneca announces that dealings have commenced in shares of Syngenta AG.
-
- 13 November 2000
- SYNGENTA SHARES PRICED AT CHF 85 FOR GLOBAL SECONDARY OFFERING Not for distribution or release in whole or in part into or from the United States, Canada, Australia or JapanAstraZeneca announces that AstraZeneca, Novartis, Syngenta and the Joint Global Co-ordinators have set a price of CHF 85 per share (equivalent to approximately £33.65 and 479.88 SEK per share) and USD 9.63 per ADS for the Global Secondary Offering of Syngenta shares. The price per ADS is based upon the noon buying rate of the New York Federal Reserve Bank on 10 November 2000 of CHF 1.7657 to USD 1.
-
- 06 November 2000
- ASTRAZENECA RECEIVES FDA APPROVAL FOR 72-HOUR INFUSION OF NAROPIN FOR POST-OPERATIVE PAIN MANAGEMENT AstraZeneca today announced that it has received approval from the US Food and Drug Administration for 72-hour infusion of Naropin®, a long-acting anaesthetic indicated for the production of local or regional anaesthesia for surgery, postoperative pain management and for obstetrical procedures.
-
- 02 November 2000
- FTC CLEARS SPIN-OFFS AND COMBINATION OF ASTRAZENECA'S AGROCHEMICALS BUSINESS AND NOVARTIS' AGRIBUSINESS AstraZeneca and Novartis AG today announced that the United States Federal Trade Commission (FTC) has approved a consent decree in connection with the spin-offs of AstraZeneca's agrochemicals business and Novartis' Agribusiness and the combination of these businesses to create Syngenta AG.
-
- 30 October 2000
- ASTRAZENECA, NOVARTIS AND SYNGENTA ANNOUNCE SYNGENTA GLOBAL SECONDARY OFFER PRICE RANGE AT CHF 85 TO 105 AstraZeneca announces that AstraZeneca, Novartis and Syngenta have set a price range of CHF 85 and CHF 105 (equivalent to approximately £32.50 to £40.10 and SEK 475 to SEK 587 ) per share for the Global Secondary Offering of Syngenta shares.
-
- 30 October 2000
- DIVESTMENT OF ZENECA's ACETOCHLOR BUSINESS AstraZeneca PLC announces that Zeneca Agrochemicals has agreed to sell its worldwide acetochlor herbicide business to Dow Agrosciences LLC.
-
- 26 October 2000
- ASTRAZENECA TO OUTSOURCE GLOBAL IT INFRASTRUCTURE SERVICES TO IBM AstraZeneca today announced that it has identified IBM as its preferred supplier of global Information Technology (IT) infrastructure services. This is subject to signature of a contract, the key terms of which have already been established in principle with IBM. A further announcement will be made once a contract has been signed.
-
- 20 October 2000
- JOINT FDA ADVISORY COMMITTEE CONFIRMS OTC PRILOSEC® (OMEPRAZOLE) SAFETY AND EFFICACY Requests Further Data
-
- 17 October 2000
- ASTRAZENECA SIGNS LICENSING AGREEMENT WITH NORTRAN AstraZeneca PLC ('AstraZeneca') announced today the execution of a licensing agreement with Nortran Pharmaceuticals Inc. ('Nortran'), a Canadian based drug discovery company. Nortran will grant AstraZeneca an exclusive world-wide licence to market a novel antiarrhythmic drug candidate in exchange for upfront, milestone and royalty payments. AstraZeneca will pay for development and marketing costs. This agreement further strengthens AstraZeneca's cardiovascular portfolio.
-
- 12 October 2000
- TWO STUDIES REPORT ENCOURAGING NEW DATA ON LONG-TERM EFFECTS OF PULMICORT® ON ASTHMA CONTROL AND GROWTH IN CHILDREN Two landmark studies reported today in the New England Journal of Medicine show encouraging new data on asthma management and children's growth with long-term use of Pulmicortâ (budesonide), an inhaled corticosteroid, made by AstraZeneca. Given the chronic nature of persistent asthma and the likely need for medications to be used for long periods of time, each of the studies -- one conducted by the National Institutes of Health (NIH), the other by world-renown asthma specialists in Denmark -- examined the
-
- 11 October 2000
- ASTRAZENECA AND NOVARTIS SHAREHOLDERS APPROVE SYNGENTA TRANSACTION AstraZeneca PLC announces that, at its Extraordinary General Meeting held in London earlier today, shareholder approval was given for the declaration and payment by the AstraZeneca Board of a dividend of Syngenta shares to holders of AstraZeneca shares on the relevant record date. The approval of this dividend will facilitate implementation of the previously announced proposed demerger of Zeneca Agrochemicals and its merger with Novartis Agribusiness to form Syngenta.
-
- 09 October 2000
- ASTRAZENECA RECEIVES FURTHER JUDGEMENT IN AUSTRALIAN OMEPRAZOLE PATENT DISPUTE AstraZeneca today announced that it will seek special leave to appeal against a judgement delivered in the Full Federal Court of Australia in Sydney in a dispute with the generic pharmaceutical company, Alphapharm Pty Limited, about the formulation patent for omeprazole - the substance used in Losec® , a treatment for acid-related disorders, such as peptic ulcers.
-
- 27 September 2000
- 'ZOLADEX' AS EFFECTIVE AS 'STANDARD' CHEMOTHERAPY IN EARLY BREAST CANCER New data pave the way for increased treatment choice in early disease
-
- 20 September 2000
- ASTRAZENECA FILES LAWSUIT AGAINST MUTUAL PHARMACEUTICAL AstraZeneca announced today that it has filed a lawsuit in Pennsylvania against Mutual Pharmaceutical Company, Inc. for patent infringement.
-
- 19 September 2000
- ASTRAZENECA RETAINS US PATENT RIGHTS TO WORLD'S LEADING BREAST CANCER DRUG--NOLVADEX® The Federal District Court in Boston has ruled that AstraZeneca's US patent covering its leading breast cancer drug Nolvadex® (tamoxifen) is valid and enforceable. In reaching this decision, District Judge Reginald Lindsay and a jury rejected the patent challenge asserted by the generic drug company, Pharmachemie B.V. As a result, the sale of tamoxifen citrate in the United States by Pharmachemie is prohibited until AstraZeneca's patent expires.
-
- 18 September 2000
- ASTRAZENECA CIRCULATES SYNGENTA MERGER INFORMATION TO SHAREHOLDERS EGM NOTICE
-
- 08 September 2000
- ASTRAZENECA FILES LAWSUIT AGAINST MYLAN AstraZeneca today announced that it has filed a lawsuit in New York against Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc. (Mylan) for patent infringement.
-
- 06 September 2000
- ASTRAZENECA RECEIVES FDA APPROVAL TO MARKET ATACAND HCT™ AstraZeneca announced today the approval of Atacand HCT™ (candesartan cilexetil-hydrochlorothiazide) by the U.S. Food and Drug Administration (FDA) for second-line treatment of hypertension. Atacand HCT combines the angiotensin II receptor blocker (ARB) Atacand® with the diuretic hydrochlorothiazide, providing physicians with another treatment option for those patients who are unable to control their hypertension with a single agent.
-
- 04 September 2000
- FDA APPROVES ARIMIDEX - A NEW FIRST LINE TREATMENT OPTION FOR BREAST CANCER AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved its breast cancer treatment Arimidex™ as a new treatment option for post-menopausal women first diagnosed with advanced or locally advanced breast cancer whose cancers are hormone receptive. Arimidex is the first aromatase inhibitor to be approved for first-line treatment in the U.S.
-
- 29 August 2000
- ASTRAZENECA RECEIVES FIRST APPROVAL FOR SYMBICORT TURBUHALER® FOR THE TREATMENT OF ASTHMA AstraZeneca has gained its first approval for Symbicort Turbuhalerv® , a new and innovative asthma treatment. Containing the corticosteroid budesonide and fast and long-acting bronchodilator formoterol in a single inhaler (Turbuhaler® ), Symbicort® is being hailed as a significant new step in the field of asthma management.
-
- 09 August 2000
- FDA APPROVES PULMICORT RESPULES - FOR CHILDREN AND INFANTS AstraZeneca today announced that Pulmicort Respules (budesonide inhalation suspension), its new asthma medication for young children and infants, is now approved by the U.S. Food and Drug Administration (FDA). As the first and only asthma treatment approved for children and infants as young as 12 months, Pulmicort Respules represents an innovative approach to inhaled corticosteroid delivery in young children and is the first and only corticosteroid to be available as a nebulized formulation. Nebulization is
-
- 01 August 2000
- ASTRAZENECA HALF YEAR RESULTS FIGURES Consolidated Profit and Loss Account. Download PDF (44Kb)
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD - Stockholm
-
310.10 SEK
At Nov 21, 2009 4:47 AM GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
